Lucinda Warren Joins Cue Biopharma as Chief Business Officer
BOSTON – Cue Biopharma, Inc. (NASDAQ: CUE), a forward-thinking clinical-stage biopharmaceutical company, has strengthened its leadership team by appointing Lucinda Warren as the new chief business officer. With over 30 years of extensive experience in business development, strategic transactions, and portfolio optimization, Ms. Warren is a seasoned expert in the biopharmaceutical industry.
Lucinda Warren’s Impressive Background
Prior to her role at Cue Biopharma, Ms. Warren held key positions at major companies such as Johnson & Johnson and Janssen. Most recently, she served as the vice president of business development for Neuroscience and the Japan Region at Johnson & Johnson from 2014 to 2024. In this capacity, she led comprehensive business development initiatives, which included licensing and forming strategic alliances, while also playing a vital role in building high-performing teams and optimizing resources.
Aligning Strategic Interests
The leadership team at Cue Biopharma is excited about Ms. Warren's appointment, viewing her extensive experience as an ideal match for the company's corporate goals. Daniel Passeri, CEO of Cue Biopharma, remarked, “Lucinda’s broad professional expertise and experience will enhance our ability to seize timely opportunities in developing our growing platform of potentially groundbreaking immunotherapies.” This statement highlights the company's dedication to forming strategic partnerships and collaborations to deliver impactful health solutions.
Ms. Warren’s Vision for Cue Biopharma
Expressing her enthusiasm for this new opportunity, Ms. Warren stated, “I look forward to joining Cue Biopharma and supporting the team as we drive successful execution of our strategic business initiatives.” Her commitment to advancing the company’s objectives underscores the significance of her role during this crucial phase of corporate development.
About Cue Biopharma
Based in Boston, Cue Biopharma is pioneering the development of a unique class of injectable biologics aimed at engaging and modulating disease-specific T cells directly within patients' bodies. Their proprietary Immuno-STAT™ platform focuses on selectively targeting T cells to harness the body's innate immune potential while minimizing the side effects typically associated with systemic immune modulation.
Company Leadership and Board
Led by a highly experienced management team, Cue Biopharma's Board of Directors possesses deep expertise in immunology and the clinical development of protein biologics. This strong foundation is essential for fostering innovative growth and ensuring operational success.
Connecting with Cue Biopharma
For more information about Cue Biopharma’s initiatives and advancements in therapeutic approaches, visit www.cuebiopharma.com. They are also active on social media platforms such as X and LinkedIn.
Frequently Asked Questions
What is Cue Biopharma's primary focus?
Cue Biopharma is a clinical-stage biopharmaceutical company dedicated to developing therapeutic biologics that selectively engage and modulate disease-specific T cells.
Who is the new chief business officer?
Lucinda Warren has been appointed as Chief Business Officer, bringing a wealth of experience from her previous roles at Johnson & Johnson and Janssen.
What experience does Lucinda Warren bring?
Lucinda Warren has over 30 years of experience in the pharmaceutical and biotechnology industries, with significant roles in business development and strategic transaction management.
How does Cue Biopharma’s platform work?
The Immuno-STAT™ platform is designed to target and modify T cells within the patient’s body, harnessing the immune system's potential while minimizing broad side effects.
Where is Cue Biopharma headquartered?
Cue Biopharma is headquartered in Boston, Massachusetts, where it is focused on driving innovation in therapeutic development.
